Results 241 to 250 of about 203,911 (301)

Glucagon‐like peptide‐1 receptor agonists and muscle strength changes in older adults: Risks beyond muscle mass reductions

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Gastric inhibitory polypeptide (GIP)/Glucagon‐like peptide‐1 (GLP‐1) receptor agonists are increasingly prescribed for the management of obesity and type 2 diabetes, yet research pertinent to their effects on muscle health is limited. Considering the central role of muscle strength as a sarcopenia component, this article summarizes emerging ...
Konstantinos Prokopidis
wiley   +1 more source

Pancreatic α-cell sodium-glucose cotransporter 1 (SGLT1) does not appear to contribute to hyperglucagonemia and glucose intolerance in diabetic mice. [PDF]

open access: yesEndocr J
Ikeuchi Y   +9 more
europepmc   +1 more source
Some of the next articles are maybe not open access.

Related searches:

Glucagon

Emergency Medicine, 2003
AbstractDespite its infrequent usage, glucagon is an important drug in the ED. It has both well established and less well established indications. This article reviews its role for the practising emergency physician.
  +7 more sources

Home - About - Disclaimer - Privacy